Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Unicycive Therapeutics (UNCY) Capital Expenditures (2022 - 2026)

Unicycive Therapeutics filings provide 2 years of Capital Expenditures readings, the most recent being $22000.0 for Q4 2024.

On a quarterly basis, Capital Expenditures changed N/A to $22000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $72000.0, a N/A change, with the full-year FY2025 number at $24000.0, down 66.67% from a year prior.
Capital Expenditures hit $22000.0 in Q4 2024 for Unicycive Therapeutics, down from $24000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $24000.0 in Q3 2024 to a low of $2000.0 in Q1 2022.